TY - JOUR
T1 - Emerging off-label uses for recombinant activated factor VII
T2 - Grading the evidence
AU - Enomoto, T. Miko
AU - Thorborg, Per
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2005/7
Y1 - 2005/7
N2 - Recombinant factor VIIa holds a great deal of promise as a hemostatic agent in many clinical settings; however, more large, randomized, controlled trials are needed to evaluate both the safety and efficacy of this apparently effective hemostatic agent, particularly in view of its cost. Cost-effectiveness studies are only in the planning stage for rFVIIa as of yet. To become cost-effective, dosing of rFVIIa should avoid costly returns in the operating room, shorten stays in the ICU, and prevent the need to give an additional 10 units of blood.
AB - Recombinant factor VIIa holds a great deal of promise as a hemostatic agent in many clinical settings; however, more large, randomized, controlled trials are needed to evaluate both the safety and efficacy of this apparently effective hemostatic agent, particularly in view of its cost. Cost-effectiveness studies are only in the planning stage for rFVIIa as of yet. To become cost-effective, dosing of rFVIIa should avoid costly returns in the operating room, shorten stays in the ICU, and prevent the need to give an additional 10 units of blood.
UR - http://www.scopus.com/inward/record.url?scp=21244463146&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=21244463146&partnerID=8YFLogxK
U2 - 10.1016/j.ccc.2005.04.001
DO - 10.1016/j.ccc.2005.04.001
M3 - Review article
C2 - 15992675
AN - SCOPUS:21244463146
SN - 0749-0704
VL - 21
SP - 611
EP - 632
JO - Critical Care Clinics
JF - Critical Care Clinics
IS - 3 SPEC. ISS.
ER -